Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Martin D. Meglasson is active.

Publication


Featured researches published by Martin D. Meglasson.


Journal of Pharmacology and Experimental Therapeutics | 2009

Pharmacokinetics and Pharmacodynamics of LGD-3303 [9-Chloro-2-ethyl-1-methyl-3-(2,2,2-trifluoroethyl)-3H-pyrrolo-[3,2-f]quinolin-7(6H)-one], an Orally Available Nonsteroidal-Selective Androgen Receptor Modulator

Eric G. Vajda; Francisco J. López; Peter Rix; Rob Hill; Yanling Chen; Kyoung-Jin Lee; Zhihong O'Brien; William Y. Chang; Martin D. Meglasson; Yong-Hee Lee

Selective androgen receptor modulators (SARMs) are a new class of molecules in development to treat a variety of diseases. SARMs maintain the beneficial effects of androgens, including increased muscle mass and bone density, while having reduced activity on unwanted side effects. The mechanisms responsible for the tissue-selective activity of SARMs are not fully understood, and the pharmacokinetic (PK)/pharmacodynamic (PD) relationships are poorly described. Tissue-specific compound distribution potentially could be a mechanism responsible for apparent tissue selectivity. We examined the PK/PD relationship of a novel SARM, LGD-3303 [9-chloro-2-ethyl-1-methyl-3-(2,2,2-trifluoroethyl)-3H-pyrrolo[3,2-f]quinolin-7(6H)-one], in a castrated rat model of androgen deficiency. LGD-3303 has potent activity on levator ani muscle but is a partial agonist on the preputial gland and ventral prostate. LGD-3303 never stimulated ventral prostate above intact levels despite increasing plasma concentrations of compound. Tissue-selective activity was maintained when LGD-3303 was dosed orally or by continuous infusion, two routes of administration with markedly different time versus exposure profiles. Despite the greater muscle activity relative to prostate activity, local tissue concentrations of LGD-3303 were higher in the prostate than in the levator ani muscle. LGD-3303 has SARM properties that are independent of its pharmacokinetic profile, suggesting that the principle mechanism for tissue-selective activity is the result of altered molecular interactions at the level of the androgen receptor.


Biochemical Pharmacology | 1991

Relationships between energy level and insulin secretion in isolated rat islets of langerhans: A study at various pH values

Ohta Mitsuaki; David Nelson; June Nelson; Martin D. Meglasson; Maria Erecińska

To define better the role of [ATP]/[ADP] in insulin release from pancreatic islets, changes in the adenine nucleotide ratios elicited by alterations in external pH were correlated with the secretion profiles produced by administration of two metabolic secretagogues, 16 mM glucose and 10 mM alpha-ketoisocaproic acid. Experiments were carried out in buffers with and without bicarbonate, in the pH range 6.5-7.7. Insulin release was dependent on pHe irrespective of the secretagogue used. Secretion profiles for alpha-ketoisocaproic acid were the same both with and without bicarbonate; the release was decreased below pH 7.1 but maintained at 7.4-7.7. The same pattern was seen with glucose in media buffered with Hepes. With bicarbonate present, secretion caused by high glucose showed a bell-shaped dependence on [H+], with reductions at the acid and alkaline sides of pH 7.1-7.4. [ATP] and [ADP] were higher when Hepes was the buffer, at all pH values studied. The [ATP]/[ADP] declined with increasing pH under both basal and stimulated conditions; the values were always larger after stimulation although at pH 7.7 with bicarbonate present and glucose as the stimulant the difference was very small. It is concluded that: (i) the [ATP]/[ADP] in pancreatic islets is markedly dependent on pHe; (ii) there is no straight-forward correlation between either [ATP] or the absolute value for [ATP]/[ADP] and insulin secretion; and (iii) a rise in [ATP]/[ADP] is necessary for glucose-stimulated insulin release although it is not always the rate-determining event.


Biochemical Pharmacology | 1992

Relationships between energy level and insulin secretion in isolated rat islets of langerhans: Manipulation of [ATP]/[ADP][Pi] by 2-deoxy-D-glucose

Mitsuaki Ohta; David Nelson; Jeanne M. Wilson; Martin D. Meglasson; Maria Erecińska

Perifusion of islets with nominally phosphate-free buffer containing increasing concentrations of 2-deoxy-D-glucose (2.5 to 10 mM) produced increments in high alpha-ketoisocaproic acid-induced secretion of insulin beyond those observed in the absence of the sugar analogue. 3-O-methyl-D-glucose, a poorly metabolized sugar, was without effect. Insulin release evoked by 40 mM KCl was not altered by 2-deoxyglucose. The concentration of intracellular inorganic phosphate was lower in islets perifused with 2-deoxyglucose and declined to a lower level after addition of 20 mM alpha-ketoisocaproic acid. The enhancement of alpha-ketoisocaproic acid-induced hormone secretion by 2-deoxyglucose was not seen in islets perifused with medium containing 1.5 mM phosphate; instead a small inhibition was observed. It is postulated that conditions which lower intracellular [Pi] facilitate, either directly or indirectly, hormone release although the mechanism of this effect remains to be elucidated.


Journal of Pharmacology and Experimental Therapeutics | 1993

Effect of Ca++ channel blockers on energy level and stimulated insulin secretion in isolated rat islets of Langerhans.

M Ohta; J Nelson; D Nelson; Martin D. Meglasson; M Erecińska


Journal of Medicinal Chemistry | 2001

Synthesis and Biological Activity of Aminoguanidine and Diaminoguanidine Analogues of the Antidiabetic/Antiobesity Agent 3-Guanidinopropionic Acid

Valerie A. Vaillancourt; Scott D. Larsen; Steven P. Tanis; Jeffery E. Burr; Mark A. Connell; Michele M. Cudahy; Bruce R. Evans; Peter V. Fisher; Paul D. May; Martin D. Meglasson; Deborah D. Robinson; F. Craig Stevens; John A. Tucker; and Thomas J. Vidmar; Jen H. Yu


Archive | 1993

A METHOD FOR TREATMENT OF METABOLIC DISORDERS AND METABOLISM.

Jerry R. Colca; Scott D. Larsen; Martin D. Meglasson; Steven P. Tanis


Journal of Pharmacology and Experimental Therapeutics | 2005

The Effects of a Selective Dopamine D2 Receptor Agonist on Behavioral and Pathological Outcome in 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine-Treated Squirrel Monkeys

Diane Stephenson; Martin D. Meglasson; Mark A. Connell; Mary A. Childs; Eva Hajos-Korcsok; Marina E. Emborg


Archive | 1995

Aminoguanidine carboxylates for the treatment of non-insulin-dependent diabetes mellitus

Scott D. Larsen; Valerie A. Vaillancourt; Paul D. May; Steven P. Tanis; John A. Tucker; Martin D. Meglasson; Heinrich J. Schostarez


Archive | 1991

Use of 3-guanidinopropionic acid in the treatment and prevention of metabolic disorders

Martin D. Meglasson


Archive | 1992

Composition, food product and uses of 3-guanidinopropionic acid

Martin D. Meglasson

Collaboration


Dive into the Martin D. Meglasson's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar

David Nelson

University of Pennsylvania

View shared research outputs
Top Co-Authors

Avatar

Maria Erecińska

University of Pennsylvania

View shared research outputs
Researchain Logo
Decentralizing Knowledge